[go: up one dir, main page]

DK2949668T3 - Forbedrede nanobodies tm mod tumornekrosefaktor-alfa - Google Patents

Forbedrede nanobodies tm mod tumornekrosefaktor-alfa Download PDF

Info

Publication number
DK2949668T3
DK2949668T3 DK15172289T DK15172289T DK2949668T3 DK 2949668 T3 DK2949668 T3 DK 2949668T3 DK 15172289 T DK15172289 T DK 15172289T DK 15172289 T DK15172289 T DK 15172289T DK 2949668 T3 DK2949668 T3 DK 2949668T3
Authority
DK
Denmark
Prior art keywords
nanobodies
polypeptides
against tumor
alfa
tumor cancer
Prior art date
Application number
DK15172289T
Other languages
English (en)
Inventor
Els Anna Alice Beirnaert
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2949668(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of DK2949668T3 publication Critical patent/DK2949668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
DK15172289T 2005-05-18 2006-05-17 Forbedrede nanobodies tm mod tumornekrosefaktor-alfa DK2949668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68233205P 2005-05-18 2005-05-18
EP20100175950 EP2365000A3 (en) 2005-05-18 2006-05-17 Improved nanobodiesTM against tumor necrosis factor-alpha

Publications (1)

Publication Number Publication Date
DK2949668T3 true DK2949668T3 (da) 2019-11-11

Family

ID=36954329

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06742963.9T DK1888641T3 (da) 2005-05-18 2006-05-17 Serumalbuminbindende proteiner
DK15172289T DK2949668T3 (da) 2005-05-18 2006-05-17 Forbedrede nanobodies tm mod tumornekrosefaktor-alfa
DK06742962.1T DK1888640T3 (da) 2005-05-18 2006-05-17 Forbedrede nanobodies mod tumornekrosefaktor-alfa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06742963.9T DK1888641T3 (da) 2005-05-18 2006-05-17 Serumalbuminbindende proteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06742962.1T DK1888640T3 (da) 2005-05-18 2006-05-17 Forbedrede nanobodies mod tumornekrosefaktor-alfa

Country Status (29)

Country Link
US (6) US8188223B2 (da)
EP (7) EP2479191A3 (da)
JP (4) JP5047950B2 (da)
KR (1) KR101308771B1 (da)
CN (2) CN101248087B (da)
AT (2) ATE549357T1 (da)
AU (1) AU2006249144B2 (da)
BR (2) BRPI0609224B1 (da)
CA (2) CA2608770C (da)
CR (1) CR9519A (da)
CY (1) CY1122672T1 (da)
DK (3) DK1888641T3 (da)
EC (1) ECSP077910A (da)
ES (3) ES2384164T3 (da)
HU (1) HUE045710T2 (da)
IL (3) IL186941A (da)
LT (1) LT2949668T (da)
MX (3) MX342271B (da)
NI (1) NI200700291A (da)
NO (2) NO338568B1 (da)
NZ (1) NZ562695A (da)
PL (3) PL1888641T3 (da)
PT (2) PT1888641E (da)
RU (2) RU2464276C2 (da)
SG (2) SG10201708038QA (da)
SI (3) SI1888641T1 (da)
TW (2) TWI439467B (da)
WO (2) WO2006122786A2 (da)
ZA (3) ZA200709867B (da)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
CA2608770C (en) 2005-05-18 2017-05-30 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
EP2091974A1 (en) * 2006-12-13 2009-08-26 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2008074868A1 (en) * 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides
JP2010518839A (ja) * 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2173772A2 (en) 2007-07-03 2010-04-14 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
WO2009127691A1 (en) * 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EA201100527A1 (ru) 2008-09-26 2011-10-31 Юсб Фарма С.А. Биологические продукты
MX345226B (es) * 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
EP2346900A1 (en) * 2008-10-29 2011-07-27 Wyeth LLC Methods for purification of single domain antigen binding molecules
AU2013202856B2 (en) * 2008-10-29 2016-02-11 Ablynx N.V. Formulations of single domain antigen binding molecules
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
WO2010125187A2 (en) 2009-04-30 2010-11-04 Ablynx Nv Method for the production of domain antibodies
SG176095A1 (en) 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2451839B1 (en) 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
LT3725330T (lt) 2009-09-03 2025-11-25 Stabilūs polipeptidų preparatai ir jų naudojimas
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
CA2787718C (en) 2010-02-11 2018-05-15 Ablynx Nv Methods and compositions for the preparation of aerosols
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2593476A2 (en) * 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US20130261288A1 (en) 2010-10-29 2013-10-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
KR101650995B1 (ko) * 2010-11-08 2016-08-25 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
US9284361B2 (en) 2010-11-26 2016-03-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
CN106039306A (zh) * 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
EP2714736A1 (en) 2011-05-27 2014-04-09 Ablynx N.V. Inhibition of bone resorption with rankl binding peptides
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
IN2014CN00414A (da) * 2011-06-23 2015-04-03 Ablynx Nv
EP2944653A1 (en) 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
CN108659121A (zh) * 2011-06-23 2018-10-16 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
CA2849409A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Anti-tumor necrosis factor-alpha agents and uses thereof
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
EA031182B1 (ru) 2012-03-30 2018-11-30 Бёрингер Ингельхайм Интернациональ Гмбх Ang2-связывающие молекулы
AU2013257848A1 (en) 2012-05-07 2014-11-27 The University Court Of The University Of Aberdeen Single domain binding molecule
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
EP2855526B1 (en) 2012-05-24 2018-11-07 VIB vzw Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
RU2530553C2 (ru) * 2012-11-07 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
US9315280B2 (en) * 2012-11-20 2016-04-19 Lockheed Martin Corporation Heat pipe with axial wick
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2894225A1 (fr) 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
HUE035315T2 (en) 2013-01-30 2018-05-02 Vib Vzw New chimeric polypeptides for screening and drug research purposes
JP2016512954A (ja) 2013-02-05 2016-05-12 フエー・イー・ベー・フエー・ゼツト・ウエー ムスカリン性アセチルコリン受容体の結合剤およびそれらの使用
CN105308068A (zh) 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗TNF-α抗体及其用途
AU2014217564B2 (en) 2013-02-13 2018-11-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-HER2 antibodies and uses thereof
TW201444871A (zh) 2013-02-13 2014-12-01 Lab Francais Du Fractionnement 具有修飾的糖化作用之西妥昔單抗及其用途
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
CN105358708B (zh) 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
RU2015146419A (ru) 2013-04-23 2017-05-26 Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN105874332B (zh) 2013-10-21 2019-11-12 戴埃克斯有限公司 自身免疫性疾病的诊断和治疗
JP6687525B2 (ja) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ オピオイド受容体結合剤およびその使用
AU2015238261B2 (en) * 2014-03-26 2020-11-19 Cell Medica Switzerland Ag Binding members to TNF alpha
US20170042991A1 (en) 2014-04-24 2017-02-16 Immusant, Inc. Compositions comprising gluten peptides and uses thereof
HUE056738T2 (hu) * 2014-05-16 2022-03-28 Ablynx Nv Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
WO2015175886A1 (en) 2014-05-16 2015-11-19 Children's Hospital Medical Center Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
PT3143042T (pt) * 2014-05-16 2020-09-01 Ablynx Nv Domínios variáveis de imunoglobulina
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2955554C (en) 2014-07-22 2022-07-05 Vib Vzw Methods to select for agents that stabilize protein complexes
ES2892525T3 (es) 2014-10-07 2022-02-04 Immunomedics Inc Uso neoadyuvante de conjugados anticuerpo-fármaco
EP3207048A4 (en) 2014-10-17 2018-05-30 The Broad Institute, Inc. Compositions and methods of treating muscular dystrophy
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
ES2731876T3 (es) 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Anticuerpos de dominio sencillo contra antígenos intracelulares
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
HRP20220811T1 (hr) 2015-01-08 2022-09-30 BioNTech SE Agonistička sredstva za vezanje tnf receptora
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3277317A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Peptide construct having a protease-cleavable linker
DK4089113T3 (da) * 2015-03-31 2024-02-05 Sorriso Pharmaceuticals Inc Polypeptider
EP3277711B9 (en) 2015-04-02 2023-08-16 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CA2985698C (en) 2015-05-13 2023-02-28 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
DK3294319T3 (da) 2015-05-13 2024-07-22 Ablynx Nv T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
US10973912B2 (en) 2015-06-29 2021-04-13 President And Fellows Of Harvard College Treatment for myopathy
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
EP3350595B1 (en) 2015-09-14 2021-08-04 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
NO2768984T3 (da) * 2015-11-12 2018-06-09
WO2017080850A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
TWI782898B (zh) 2015-11-18 2022-11-11 美商默沙東有限責任公司 Pd1／ctla4結合劑
JP6768800B2 (ja) 2015-11-18 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｔｌａ４結合性物質
KR102317574B1 (ko) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
US11332519B2 (en) * 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
TWI734719B (zh) 2015-12-04 2021-08-01 德商百靈佳殷格翰國際股份有限公司 在腫瘤細胞中拮抗ｗｎｔ信號傳遞之雙抗體結合部位（ｂｉｐａｒａｔｏｐｉｃ）多肽
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017134302A2 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
AU2017259876A1 (en) 2016-05-02 2018-10-25 Ablynx Nv Treatment of RSV infection
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201811280QA (en) 2016-06-23 2019-01-30 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN110177809B (zh) 2016-11-16 2023-11-03 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
KR102616835B1 (ko) 2016-12-07 2023-12-22 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
CN110191896B (zh) 2017-01-17 2023-09-29 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
CN110546160A (zh) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 靶向嵌合蛋白及其用途
SI3583125T1 (sl) 2017-02-16 2025-06-30 Sonnet BioTherapeutics, Inc. Fuzijski proteini z albumin-vezavno domeno
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110573604A (zh) 2017-02-28 2019-12-13 非营利性组织佛兰芒综合大学生物技术研究所 用于口服蛋白质递送的工具和方法
SG11201908154RA (en) 2017-03-31 2019-10-30 Ablynx Nv Improved immunogenicity assays
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
US11033636B2 (en) 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
AU2018277310B2 (en) 2017-06-02 2024-07-11 Ablynx Nv Aggrecan binding immunoglobulins
CN110691790A (zh) 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
EP3630817A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
JP7760115B2 (ja) 2017-10-31 2025-10-27 フエー・イー・ベー・フエー・ゼツト・ウエー 新規抗原結合性キメラタンパク質とその方法及び使用
WO2019133827A1 (en) * 2017-12-29 2019-07-04 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019165105A1 (en) * 2018-02-26 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019204634A1 (en) * 2018-04-20 2019-10-24 Stc. Unm Rap1-gtp, rac1-gtp and fms-like tyrosine kinase 3 ligand (flt3-l) as biomarkers for early detection of sepsis
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
DE102018122275A1 (de) 2018-09-12 2020-03-12 Osram Opto Semiconductors Gmbh Lichtemittierendes bauteil und verfahren zum betreiben eines lichtemittierenden bauteils
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
CN111138536B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 抗人血清白蛋白单域抗体的制备及其应用
CN111138537B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 一种抗人血清白蛋白抗体片段、制备方法和应用
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
CN111423509B (zh) * 2019-01-10 2021-07-09 瑞阳(苏州)生物科技有限公司 抗hsa单域抗体及其融合蛋白的亲和层析纯化方法
CN109627334B (zh) * 2019-01-29 2020-07-17 康元医疗科技(大连)有限公司 一种纳米抗体、以该纳米抗体为配基的吸附剂及其用途
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
TW202104258A (zh) 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
TW202108615A (zh) 2019-03-29 2021-03-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
KR102831011B1 (ko) 2019-04-29 2025-07-08 콘포 테라퓨틱스 엔.브이. 트랜스맴브레인 단백질, 특히 gpcr과 함께 사용하기 위한 스크리닝 방법 및 검정
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
US12472254B2 (en) 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
SG11202112927UA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
KR20220064953A (ko) 2019-06-21 2022-05-19 소리소 파마슈티컬스 인크. 폴리펩티드
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
WO2021039574A1 (ja) * 2019-08-23 2021-03-04 株式会社カネカ Ｏ結合型糖鎖修飾が抑制された重鎖抗体
CN115947846A (zh) 2019-09-12 2023-04-11 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
CN110642946A (zh) * 2019-09-30 2020-01-03 中国药科大学 一种人源化纳米抗体及其制备方法
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021078786A1 (en) 2019-10-21 2021-04-29 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
CN112746331A (zh) * 2019-10-29 2021-05-04 安升（上海）医药科技有限公司 半衰期延长的药物及其文库、以及制备方法和应用
WO2021095031A2 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
CN114980923A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
TWI861302B (zh) 2019-12-09 2024-11-11 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
CN110988361B (zh) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 人血清白蛋白去除试剂盒
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
WO2021140202A1 (en) 2020-01-08 2021-07-15 argenx BV Methods for treating pemphigus disorders
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP4106806A4 (en) 2020-02-21 2024-07-24 Harpoon Therapeutics, Inc. FLT3-BINDING PROTEINS AND METHODS OF USE
JP2023514654A (ja) 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ２のアロステリック調節因子
US20230212270A1 (en) * 2020-03-06 2023-07-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Serum albumin binding nanobody compositions and methods for using the same
WO2021213435A1 (zh) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
CN116284375A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN114106190B (zh) 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
EP4237438A4 (en) 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
CA3203141A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders
US20240052045A1 (en) 2020-12-24 2024-02-15 Vib Vzw Murine cross-reactive human ccr8 binders
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
US20240101647A1 (en) 2021-02-05 2024-03-28 Vib Vzw Sarbecovirus binders
CA3211257A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4359421A1 (en) 2021-06-23 2024-05-01 Vib Vzw Means and methods for selection of specific binders
JP2024524378A (ja) 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
CN113527502B (zh) * 2021-07-20 2023-01-17 福建医科大学 一种用于治疗类风湿性关节炎的纳米抗体重组蛋白
US20240327525A1 (en) 2021-07-30 2024-10-03 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023098846A1 (zh) 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
CN118510805A (zh) 2021-12-31 2024-08-16 山东先声生物制药有限公司 一种gprc5d抗体及其应用
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
CN116925215A (zh) * 2022-03-31 2023-10-24 普米斯生物技术(珠海)有限公司 抗血清白蛋白纳米抗体及其衍生物
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CA3249283A1 (en) 2022-05-18 2023-11-23 Vib Vzw BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
CN115028719B (zh) * 2022-05-27 2023-01-13 深圳市人民医院 血清白蛋白结合纳米抗体及其制备方法与应用
CN119317648A (zh) 2022-06-06 2025-01-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
CA3259417A1 (en) 2022-06-14 2023-12-21 Ablynx Nv UNIQUE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING THE T LYMPHOCYTE RECEPTOR
KR20250039514A (ko) 2022-06-15 2025-03-20 아르젠엑스 비브이 Fcrn/hsa 결합 분자 및 사용 방법
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4573119A1 (en) 2022-08-17 2025-06-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4628505A1 (en) 2022-10-28 2025-10-08 Genor Biopharma Co., Ltd. Novel anti-ctla4 antibody
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
KR20250135288A (ko) * 2023-01-18 2025-09-12 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 융합 폴리펩타이드의 액체 약학 조성물 및 이의 사용 방법
KR20250136390A (ko) 2023-01-20 2025-09-16 베링거 인겔하임 인터내셔날 게엠베하 IL-12 Fc 융합 단백질
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
EP4680624A1 (en) 2023-03-14 2026-01-21 Aarhus Universitet Genetically altered nfr5 receptor kinases
IL323035A (en) 2023-03-14 2025-10-01 Odyssey Therapeutics Inc Anti-CD25 antigen-binding proteins and their uses
CN121013863A (zh) 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 Tnfr2结合多肽及使用方法
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
WO2024226410A1 (en) 2023-04-24 2024-10-31 Merck Sharp & Dohme Llc Trop2 binders and conjugates thereof
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
US20250051434A1 (en) 2023-08-11 2025-02-13 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025090840A1 (en) * 2023-10-27 2025-05-01 Rutgers, The State University Of New Jersey Antigen binding molecules targeting tnf-alpha
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025147862A1 (zh) * 2024-01-09 2025-07-17 上海洛启生物医药技术有限公司 血清白蛋白结合分子及其应用
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025160546A1 (en) 2024-01-26 2025-07-31 The Johns Hopkins University Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
GB202403780D0 (en) 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US460167A (en) 1891-09-29 Car-mover
DE321017C (da) 1917-05-15 1920-05-11 Aloysius Petrus Van Leuven
SE307996B (da) 1965-11-30 1969-01-27 Asea Ab
US4352678A (en) 1978-10-02 1982-10-05 Lever Brothers Company Thickened abrasive bleaching compositions
US4722896A (en) 1981-01-26 1988-02-02 The Beth Israel Hospital Association Method for affinity purification of hybridoma antibodies
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4735898A (en) 1985-07-16 1988-04-05 The University Of Virginia Alumini Patents Foundation Monoclonal antibodies and method of identifying species using the same
JPS62175426A (ja) 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
AU640400B2 (en) 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ234246A (en) 1990-03-16 1992-06-26 Flexitech Consulting Services Form filling powdered material packages using interleaved plastics/paper packaging
GB9016299D0 (en) 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590060B1 (en) 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0568332B1 (en) 1992-04-28 1999-07-28 Sumitomo Rubber Industries, Ltd. Solid golf ball
PT651805E (pt) 1992-07-17 2007-02-28 Dana Farber Cancer Inst Inc Método de ligação intracelular de moléculas-alvo
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
JP3616091B2 (ja) 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6268894A (en) 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
ES2155854T3 (es) 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
AU4964896A (en) 1995-01-19 1996-08-07 Research Foundation Of The State University Of New York, The Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
ATE184613T1 (de) 1995-09-22 1999-10-15 Novo Nordisk As Varianten des grünen fluoreszenzproteins, gfp
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US5895466A (en) 1997-08-19 1999-04-20 At&T Corp Automated natural language understanding customer service system
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
ES2192060T5 (es) 1998-07-06 2009-05-01 Perkinelmer Cellular Sciences Belgium Bvba Ensayo de bioluminiscencia para agonistas o antagonistas de un receptor acoplado al calcio.
CN1323355A (zh) 1998-08-13 2001-11-21 美国吉诺米克斯公司 光学鉴定聚合物
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
AU779162B2 (en) 1999-02-05 2005-01-06 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
ATE364696T1 (de) 1999-03-15 2007-07-15 Univ British Columbia Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
OA11862A (en) 1999-04-22 2006-03-02 Unilever Nv Inhibition of viral infection using monovalent antigen-binding proteins.
DE10027695A1 (de) 1999-05-27 2001-04-19 Max Delbrueck Centrum Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind
IL147022A0 (en) 1999-06-18 2002-08-14 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
US7358096B1 (en) 1999-11-29 2008-04-15 Conopco, Inc. Immobilisation of proteins
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
UA76708C2 (uk) * 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
AU2001294132A1 (en) 2000-10-20 2002-04-29 Firmenich S.A. Alcohol-free perfuming composition
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2003005053A1 (de) 2001-07-04 2003-01-16 Siemens Aktiengesellschaft Verfahren zur intensitätskorrektur eines magnetresonanzbildes
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
FR2829940A1 (fr) 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR20050044405A (ko) 2001-11-12 2005-05-12 메르크 파텐트 게엠베하 변형된 항-ｔｎｆ 알파 항체
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
WO2003048902A2 (en) 2001-12-03 2003-06-12 Dyax Corporation Library screening
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
DE10225567B4 (de) 2002-06-10 2006-07-06 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG Kommunikationsverfahren und System hierfür
WO2004001064A2 (en) * 2002-06-21 2003-12-31 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US20080008713A1 (en) 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1388571A1 (de) 2002-08-08 2004-02-11 Ciba Spezialitätenchemie Pfersee GmbH Polyorganosiloxanzusammensetzung enthaltend quaternäre Ammoniumgruppen
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
ATE517922T1 (de) 2002-11-08 2011-08-15 Ablynx Nv Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US7539903B2 (en) 2003-06-30 2009-05-26 Siemens Aktiengesellschaft Method for monitoring the execution of a program by comparing a request with a response and introducing a falsification in a response
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
EP1512696A1 (en) 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US7432238B2 (en) 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2608770C (en) 2005-05-18 2017-05-30 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
PT2321352E (pt) 2008-07-18 2016-03-18 Domantis Ltd Composições monovalentes para ligação a cd28 e métodos de utilização
CN103168104B (zh) 2010-07-22 2016-09-28 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
DK4089113T3 (da) * 2015-03-31 2024-02-05 Sorriso Pharmaceuticals Inc Polypeptider
WO2017167997A1 (en) * 2016-03-31 2017-10-05 Vhsquared Limited Compositions

Also Published As

Publication number Publication date
IL186941A (en) 2014-05-28
SI1888641T1 (sl) 2012-05-31
IL186941A0 (en) 2008-02-09
CN103254309A (zh) 2013-08-21
ZA200901011B (en) 2010-04-28
BRPI0609224B1 (pt) 2021-08-17
EP1888641A1 (en) 2008-02-20
TWI439467B (zh) 2014-06-01
NO345340B1 (no) 2020-12-21
CN101248087B (zh) 2012-09-26
CA2608770C (en) 2017-05-30
US20090028880A1 (en) 2009-01-29
WO2006122787A1 (en) 2006-11-23
PT2949668T (pt) 2019-10-24
BR122013001996B1 (pt) 2022-02-01
MX363423B (es) 2019-03-22
NO20075853L (no) 2007-12-19
CN101248087A (zh) 2008-08-20
PL2949668T3 (pl) 2020-03-31
EP2172484A2 (en) 2010-04-07
EP1888641B1 (en) 2011-12-14
US9067991B2 (en) 2015-06-30
ATE537188T1 (de) 2011-12-15
EP2479191A3 (en) 2013-03-13
IL225347A (en) 2017-05-29
AU2006249144A1 (en) 2006-11-23
RU2007142444A (ru) 2009-06-27
JP2012167112A (ja) 2012-09-06
IL250946B (en) 2018-08-30
RU2017133794A (ru) 2019-03-28
JP6484660B2 (ja) 2019-03-13
NI200700291A (es) 2008-05-12
EP2172484A3 (en) 2010-05-19
US20200079844A1 (en) 2020-03-12
CA2962819A1 (en) 2006-11-23
CA2608770A1 (en) 2006-11-23
ATE549357T1 (de) 2012-03-15
SG10201708038QA (en) 2017-10-30
NO20161028A1 (no) 2007-11-19
LT2949668T (lt) 2019-11-11
US20230031229A1 (en) 2023-02-02
EP1888640B1 (en) 2012-03-14
JP2008539772A (ja) 2008-11-20
IL225347A0 (en) 2013-06-27
RU2017133794A3 (da) 2020-12-23
MX2007014359A (es) 2008-02-06
EP2949668A1 (en) 2015-12-02
TW200716671A (en) 2007-05-01
WO2006122786A2 (en) 2006-11-23
JP2015157850A (ja) 2015-09-03
CA2962819C (en) 2021-07-27
EP2479191A2 (en) 2012-07-25
EP2949668B1 (en) 2019-08-14
JP5047950B2 (ja) 2012-10-10
WO2006122786A3 (en) 2007-03-22
KR101308771B1 (ko) 2013-09-23
CY1122672T1 (el) 2021-03-12
KR20080011395A (ko) 2008-02-04
ES2778123T3 (es) 2020-08-07
ES2384164T3 (es) 2012-07-02
SI1888640T1 (sl) 2012-07-31
NO338568B1 (no) 2016-09-05
DK1888640T3 (da) 2012-06-18
SG184709A1 (en) 2012-10-30
JP5788359B2 (ja) 2015-09-30
HUE045710T2 (hu) 2020-01-28
CN103254309B (zh) 2017-09-26
PT1888641E (pt) 2012-03-19
EP1888640A2 (en) 2008-02-20
AU2006249144B2 (en) 2011-11-17
US20140335101A1 (en) 2014-11-13
ZA201100385B (en) 2012-09-26
RU2634381C2 (ru) 2017-10-26
IL250946A0 (en) 2017-04-30
PL1888640T3 (pl) 2012-08-31
JP6420200B2 (ja) 2018-11-07
SI2949668T1 (sl) 2019-11-29
US20150353635A1 (en) 2015-12-10
DK1888641T3 (da) 2012-04-23
EP2365000A2 (en) 2011-09-14
ZA200709867B (en) 2008-10-29
HK1113685A1 (en) 2008-10-10
US8188223B2 (en) 2012-05-29
JP2017186318A (ja) 2017-10-12
PL1888641T3 (pl) 2012-05-31
ES2379283T3 (es) 2012-04-24
HK1215953A1 (en) 2016-09-30
EP3613767A1 (en) 2020-02-26
NZ562695A (en) 2011-05-27
EP2365000A3 (en) 2013-01-16
BRPI0609224A2 (pt) 2011-10-18
US20170342146A1 (en) 2017-11-30
CR9519A (es) 2008-10-17
TWI395755B (zh) 2013-05-11
RU2464276C2 (ru) 2012-10-20
MX342271B (es) 2016-09-21
TW201321410A (zh) 2013-06-01
ECSP077910A (es) 2008-03-26
US11472871B2 (en) 2022-10-18
RU2012126722A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
CY1122672T1 (el) Βελτιωμενα nanobodiestm εναντι του παραγοντα νεκρωσης ογκων αλφα
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
PH12012502272A1 (en) Biological materials related to her3
ATE541283T1 (de) Verfahren zum mischen von farben in einem display
WO2006122825A3 (en) Single domain vhh antibodies against von willebrand factor
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2005123916A3 (en) Glycosylation-disrupted factor vii variants
WO2005024006A3 (en) Coagulation factor vii polypeptides